Colorectal Cancer RECHALLENGE

ABSTRACT: Primary Objective: * To demonstrate that re-challenge with an oxaliplatin based regimen (modified FOLFOX-6) will provide a clinical disease control rate (DCR) of at least 20% at the end of the chemotherapy. Secondary Objective: * To evaluate other measures of tumour’s responses and safety.

DISEASE(S): Colorectal Neoplasms

PROVIDER: 2078904 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR